Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Introduction: The advent of tumor necrosis factor (TNF) antagonists represented a radical
change in the management of inflammatory bowel disease (IBD). Both in short-and long …

Background Anti‐tumour necrosis factor (anti‐TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …

Introduction: Efficacy and safety are key aspects when choosing therapies for patients with
inflammatory bowel diseases (IBD). While several randomized trials and indirect …

Opinion statement Anti-tumor necrosis factor-α (anti-TNF) therapy has become a very
important modality in the treatment of patients with inflammatory bowel disease. A number of …

Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

Background One‐third of patients with Crohn's disease (CD) or ulcerative colitis (UC)
receiving anti‐TNF s do not respond to treatment, and a relevant proportion experience loss …

Inflammatory bowel diseases (IBDs) are chronic conditions of the gastrointestinal tract in
which dysregulated immune responses cause persistent inflammation of the gut mucosa …

Since their appearance in the armamentarium for inflammatory bowel disease (IBD) more
than a decade ago, antitumor necrosis factor (TNF) inhibitors have demonstrated beneficial …